Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3107-3113

  Espinel Ingroff, A ^a   Chowdhary, A ^b   Cuenca Estrella, M ^c   Fothergill, A ^d   Fuller, J ^e   Hagen, F ^f   Govender, N ^g   Guarro, J ^h   Johnson, E ⁱ   Lass Florl C ^j   Lockhart, S R ^k   Martins, M A ^l   Meis, J F ^f,m   Melhem, M S C ^l   Ostrosky Zeichner, L ⁿ   Pelaez, T ^o   Pfaller, M A ^p   Schell, W A ^q   Trilles, L ^r   Kidd, S ^s   Turnidges, J ^s,t   more..

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF DELHI   (India)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^g NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^h INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

ⁱ NHS BLOOD AND TRANSPLANT   (United Kingdom)

^j INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^k CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^l INSTITUTO ADOLFO LUTZ   (Brazil)

^m RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ UNIVERSITY OF TEXAS   (United States)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^p UNIVERSITY OF IOWA   (United States)

^q DUKE UNIVERSITY MEDICAL CENTER   (United States)

^r Funda??o Oswaldo Cruz   (Brazil)

^s WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^t UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; AUSTRALIA; BRAZIL; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; EPSILOMETER TEST; EUROPE; FUNGAL DETECTION; INDIA; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SOUTH AFRICA; UNITED STATES; WILD TYPE;

AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLUCYTOSINE; MICROBIAL SENSITIVITY TESTS;

EID: 84861125770     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06252-11     Document Type: Article

References (51)

1. Block ER, Jennings AE, Bennett JE. 1973. 5-Fluorocytosine resistance in Cryptococcus neoformans isolates. Antimicrob. Agents Chemother. 3:649-656.
2. Bovers M, Hagen F, Boekhout T. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species-complex. Rev. Iberoam. Micol. 25: S4-S12. (Pubitemid 351518336)
3. Brandt ME, et al. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069. (Pubitemid 32988829)
4. Byrnes EJ, et al. 2011. A diverse population of Cryptococcus gattii molecular type VGIII in Southern Californian HIV/AIDS patients. PLoS Pathog. 7:e1002205. doi:10.1371/journal.ppat.1002205.
5. Byrnes EJ, et al. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6:e1000850. doi:10.1371/journal.ppat.1000850.
6. Calvo BM, et al. 2001. Antifungal susceptibilities, varieties and electrophoretic karyotypes of Cryptococcus neoformans from Brazil, Chile and Venezuela. J. Clin. Microbiol. 39:2348-2350. (Pubitemid 32531513)
7. Chong HS, Dagg R, Malik R. 2010. In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. J. Clin. Microbiol. 48:4115-4120.
8. Chowdhary A, et al. 2011. In vitro antifungal susceptibilities and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and C. gattii serotype B from northwestern India. J. Med. Microbiol. 60:961-967.
9. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, third informational supplement. CLSI document M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37:296-305.
12. Dannaoui E, et al. 2006. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis. Antimicrob. Agents Chemother. 50:2464-2470. (Pubitemid 43993187)
13. De Bedout C, et al. 1999. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and C. neoformans var. gattii. Rev. Iberoam. Micol. 16:36-39. (Pubitemid 29166856)
14. Espinel-Ingroff A. 2008. Mechanisms of resistance to antifungal agents: yeasts and filamentous fungi. Rev. Iberoam. Micol. 25:101-106. (Pubitemid 351798337)
15. Espinel-Ingroff A, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2). J. Clin. Microbiol. 48: 3251-3257.
16. Espinel-Ingroff A, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for caspofungin and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:2855-2859.
17. Espinel-Ingroff A, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for amphotericin B and Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document). Antimicrob. Agents Chemother. 55:5150-5154.
18. Gomez-Lopez A, et al. 2008. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 14:727-730.
19. Hagen F, et al. 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob. Agents Chemother. 54:5139-5149.
20. Hagen F, et al. 21 March 2012. Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. J. Clin. Microbiol. [Epub ahead of print.] doi:10.1128/JCM.06750-11.
21. Harris JR, et al. 2011. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin. Infect. Dis. 53: 1188-1195.
22. Hospenthal DR, Bennett JE. 1998. Flucytosine monotherapy for cryptococcosis. Clin. Infect. Dis. 27:260-264. (Pubitemid 28365747)
23. Illnait-Zaragozi MT, et al. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52:1580-1582.
24. Iqbal N, et al. 2010. Correlation of genotypes and in vitro susceptibilities of Cryptococcus gattii from the Pacific Northwest of the United States. J. Clin. Microbiol. 48:539-544.
25. Joseph-Horne T, Loeffler RS, Hollomon DW, Kelly SL. 1996. Amphotericin B resistant isolates of Cryptococcus neoformans without alteration in sterol biosynthesis. J. Med. Vet. Mycol. 34:223-225. (Pubitemid 26186576)
26. Kahlmeter G, et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
27. Kanafani ZA, Perfect JR. 2008. Resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46:120-128. (Pubitemid 351263573)
28. Kelly SL, et al. 1994. Resistance to amphotericin B associated with defective sterol delta 8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient. FEMS Microbiol. Lett. 122:39-42. (Pubitemid 24275247)
29. Kidd SE, et al. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258-17263. (Pubitemid 39627807)
30. Larsen RA, et al. 2011. Correlation of susceptibility testing of Cryptococcus neoformans to amphotericin B with clinical outcome. Antimicrob. Agents Chemother. 55:5624-5630.
31. Lin X, Heitman J. 2006. The biology of the Cryptococcus neoformans species complex. Annu. Rev. Microbiol. 60:69-105. (Pubitemid 44627941)
32. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. 2003. Amphotericin B: time for a new "gold standard." Clin. Infect. Dis. 37:415-425. (Pubitemid 36976501)
33. Pan W, et al. Genotypic differences and multiresistance occur in Asian populations of Cryptococcus neoformans var. grubii. PLoS One, in press.
34. Perfect JR, Cox JM. 1999. Drug resistance in Cryptococcus neoformans. Drug Resist. Updat. 2:259-269. (Pubitemid 29526248)
35. Perfect JR, et al. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291-322.
36. Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M. 2005. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans. J. Antimicrob. Chemother. 56:1144-1147. (Pubitemid 43009837)
37. Pfaller MA, et al. 2009. Wild type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 47:3142-3146.
38. Pfaller MA, et al. 2009. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-year analysis of susceptibilities of noncandidal yeast species to fluconazole and voriconazole determined by the CLSI standardized disk diffusion testing. J. Clin. Microbiol. 47:117-123.
39. Pfaller MA, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
40. Pfaller MA, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-h CLSI broth microdilution. J. Clin. Microbiol. 49:630-637.
41. Pfaller MA, Boyken L, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit. Rev. Microbiol. 36:1-53.
42. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time to harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
43. Rodriguez-Tudela JL, et al. 2008. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus. Antimicrob. Agents Chemother. 52:2468-2472. (Pubitemid 351915677)
44. Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. 2007. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 51:383-385. (Pubitemid 46047737)
45. Thompson GR, et al. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311.
46. Trilles L, et al. 2008. Regional patterns of the molecular types of Cryptococcus neoformans and C. gattii in Brazil. Mem. Inst. Oswaldo Cruz 103: 455-462.
47. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. 2012. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med. Mycol. 50:328-332.
48. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
49. Vanden Bossche H, et al. 1994. Mechanisms and clinical impact of antifungal drug resistance. J. Med. Vet. Mycol. 32:189-202.
50. Whelan WL. 1987. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans. Crit. Rev. Microbiol. 15: 45-56.
51. White TC, Hoot SJ. 2011. Mechanisms of resistance to antifungal agents, p 2008-2019. In Versalovic J, et al (ed). Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.